Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apellis' Empaveli Poised To Give Soliris A Run In PNH

New Drug Reaches The Market With Broad Label And Competitive Pricing

Executive Summary

The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.

You may also be interested in...



NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck

NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.

Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options

The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.

Apellis Has New Hope for Pegcetacoplan With Longer-Term Data

One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel